Quantitative assessment of the anticoagulant in plasma units collected by plasmapheresis.


Journal

Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360

Informations de publication

Date de publication:
06 2019
Historique:
received: 26 12 2018
revised: 14 02 2019
accepted: 14 02 2019
pubmed: 16 3 2019
medline: 29 5 2020
entrez: 16 3 2019
Statut: ppublish

Résumé

To date, the quantification of the anticoagulant (ACD-A) in plasma units has been based on theoretical calculations. An accurate quantification could help minimize the risks associated with plasmapheresis, given that the total ACD-A used during the procedure is distributed between the donor and the plasma unit. Our aim was to experimentally quantify the volume of ACD-A in units collected by plasmapheresis. We used proton nuclear magnetic resonance spectroscopy to measure the ACD-A volume in 295 plasma units collected by the Azienda USL-IRCCS of Reggio Emilia, Italy. We analyzed the determinants of the differences between estimated and measured ACD-A through multivariate regression models. The experimentally measured ACD-A in plasma units was variable, with 45% of the samples showing a discrepancy of more than 15 mL compared to the manufacturer's estimate. ACD-A was underestimated for higher density of the units (p < 0.0005); a weak association was also observed with triglycerides (underestimated for higher levels, p = 0.015) and sex (overestimated in females, p = 0.008), but our model explained only 35% of the individual variability. The manufacturer's algorithms do not accurately estimate the ACD-A in units collected by plasmapheresis. Donor-related characteristics may affect ACD-A distribution between donor and plasma unit, thereby explaining the discrepancies between estimate and measurement. Errors in the estimate of the ACD-A actually received by donors could hamper studies on dose-response relationship between anticoagulant and adverse reactions. Our work should stimulate research on tailored procedures aimed at minimizing the anticoagulant received by donors and increasing plasmapheresis safety.

Sections du résumé

BACKGROUND
To date, the quantification of the anticoagulant (ACD-A) in plasma units has been based on theoretical calculations. An accurate quantification could help minimize the risks associated with plasmapheresis, given that the total ACD-A used during the procedure is distributed between the donor and the plasma unit. Our aim was to experimentally quantify the volume of ACD-A in units collected by plasmapheresis.
STUDY DESIGN AND METHODS
We used proton nuclear magnetic resonance spectroscopy to measure the ACD-A volume in 295 plasma units collected by the Azienda USL-IRCCS of Reggio Emilia, Italy. We analyzed the determinants of the differences between estimated and measured ACD-A through multivariate regression models.
RESULTS
The experimentally measured ACD-A in plasma units was variable, with 45% of the samples showing a discrepancy of more than 15 mL compared to the manufacturer's estimate. ACD-A was underestimated for higher density of the units (p < 0.0005); a weak association was also observed with triglycerides (underestimated for higher levels, p = 0.015) and sex (overestimated in females, p = 0.008), but our model explained only 35% of the individual variability.
CONCLUSION
The manufacturer's algorithms do not accurately estimate the ACD-A in units collected by plasmapheresis. Donor-related characteristics may affect ACD-A distribution between donor and plasma unit, thereby explaining the discrepancies between estimate and measurement. Errors in the estimate of the ACD-A actually received by donors could hamper studies on dose-response relationship between anticoagulant and adverse reactions. Our work should stimulate research on tailored procedures aimed at minimizing the anticoagulant received by donors and increasing plasmapheresis safety.

Identifiants

pubmed: 30875439
doi: 10.1111/trf.15244
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2113-2120

Informations de copyright

© 2019 AABB.

Auteurs

Filippo Vurro (F)

Istituto dei Materiali per Elettronica e il Magnetismo (CNR-IMEM), Parma, Italy.

Lucia Merolle (L)

Transfusion Medicine Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.

Chiara Marraccini (C)

Transfusion Medicine Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.

Maura Parisi (M)

Transfusion Medicine Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.

Laura Canovi (L)

Transfusion Medicine Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.

Barbara Erta (B)

Transfusion Medicine Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.

Annalisa Santachiara (A)

AVIS Provinciale, Reggio Emilia, Italy.

Laura Bonvicini (L)

Epidemiology Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.

Paolo Giorgi Rossi (P)

Epidemiology Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.

Roberto Baricchi (R)

Transfusion Medicine Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.

Thelma A Pertinhez (TA)

Transfusion Medicine Unit, Azienda USL-IRCCS, Reggio Emilia, Italy.
Department of Medicine and Surgery, University of Parma, Parma, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH